Study Group: Radiologists (US)
Council Members in this Study Group: 708
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
John HewettPartner
Pacific Interventional
J. Joseph Hewett, MD is the Medical Director of Vascular Access Centers of South Los Angeles, Vascular Access Center of Los Angeles, and Newport Cancer Care Diagnostic Imaging and Interventions. He is a managing partner in Pacific Interventional which...
- Johnson Lightfoote
Medical Director Department of Radiology
POMONA VALLEY HOSPITAL MEDICAL CENTERJohnson Lightfoote, MD, MBA, is Medical Director of Radiology at Pomona Valley Hospital Medical Center and past Medical Director of University of Southern California University Hospital. His responsibilities include management of imaging services; implementation...
- Martin Fuss
Radiation Oncologist
OREGON HEALTH & SCIENCE UNIVERSITY - CCMartin Fuss, MD, is a Professor and Program Director of Image-Guided Radiation Therapy (IGRT) in the Department of Radiation Medicine at Oregon Health and Science University. Previously, Dr. Fuss was an Associate Professor in the Department of Radiation...
- Jon Strasser
Assistant Professor of Radiation Oncology
THOMAS JEFFERSON UNIVERSITYJon Strasser, MD, is an Assistant Professor of Radiation Oncology at Thomas Jefferson University and an Attending Physician in Radiology, Oncology, and Radiation Oncology at the Helen F. Graham Cancer Center of the Christiana Care Health System in Delaware....
- Eric Choi
Associate Professor of Surgery and Radiology
Washington University in St. Louis-School of MedicineEric Choi, MD, is an Associate Professor of Surgery and Radiology at Washington University School of Medicine, in Missouri. Dr. Choi is experienced in the treatment of of vascular diseases including aortic aneurysm, carotid artery disease, peripheral...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Particle Beam Technology - Costly and a limited utility
October 26, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.
-
August 21, 2008
Analysis by: Marc Hamet, Clinical Professor,Heart Stents No Better Than Drugs for Chest Pain Over Time | www.bloomberg.com
This article could easily be spun as a victory for stent efficacy.
-
May 27, 2008
Look to England's example for ways to solve America's health-care problem | www.sltrib.com
A single payer, national system does work, but may not necessarily be in the best interest of all parties. Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.
-
Watch out Tomo....here comes some competition
November 16, 2007
Varian's New Rapid Arc Delivery | www.varian.com
Varian and Elekta's new arc treatments improve workflow, efficiency, and give radiation oncologists a better alternative to tomotherapy.
-
October 26, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
This is a big hit for Pfizer - a costly product they licensed due to lack of good pipeline products. Unfortunatley, I don't think they anticipated the issues surrounding the complexity of inhaled insulin, properly marketed the product, or did enough research on the patient side (ie compliane, interest), etc. As such, Pfizer, and it's share holders will pay a price for this costly investment. However, Pfizer will survive, and will keep on buying other products to develop and sell
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Director
- Allied Health Professional
- Physician - Division Head
- Physician - Department Chair
- Professor
- President
- Partner